Philadelphia, PA, United States of America

Allitia DiBernardo

USPTO Granted Patents = 2 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Allitia DiBernardo: Innovator in Multiple Sclerosis Treatment

Introduction

Allitia DiBernardo is a prominent inventor based in Philadelphia, PA, known for his significant contributions to the field of medicine, particularly in the treatment of multiple sclerosis. With a total of 2 patents, DiBernardo has made strides in developing innovative methods that enhance patient care and treatment efficacy.

Latest Patents

DiBernardo's latest patents focus on methods of treating multiple sclerosis. The disclosures relate to pharmaceutical products containing ponesimod, which include instructions for its use, methods for selling the drug product, and strategies for reducing clinical management events before or during treatment. These advancements aim to improve the quality of life for patients suffering from this debilitating condition.

Career Highlights

DiBernardo is currently associated with Vanda Pharmaceuticals Inc., where he continues to work on groundbreaking research and development in the pharmaceutical industry. His expertise and dedication to innovation have positioned him as a key figure in the medical community.

Collaborations

Throughout his career, DiBernardo has collaborated with talented professionals, including Tatiana Sidorenko and Michel Burcklen. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the development of effective treatment methods.

Conclusion

Allitia DiBernardo's work in the field of multiple sclerosis treatment exemplifies the impact of innovation in medicine. His patents and ongoing research contribute significantly to improving patient outcomes and advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…